COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03417154
Recruitment Status : Suspended (Treatment ineffective)
First Posted : January 31, 2018
Last Update Posted : January 10, 2020
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota

No Study Results Posted on for this Study
Recruitment Status : Suspended
Estimated Primary Completion Date : February 2021
Estimated Study Completion Date : February 2023